Heavy menstrual bleeding is prolonged (>7 days) or excessive (>10 mL) uterine bleeding occurring at regular intervals over several menstrual cycles.
It is menstrual blood loss that is excessive and interferes with patient's physical, emotional, social and quality of life.
It is also referred to as menorrhagia or hypermenorrhea.
It is a common problem in women of reproductive age that usually causes anemia.
Uterine fibroids and polyps are the most common pathology identified.
Use of a levonorgestrel intrauterine device (IUD) can help reduce menstrual bleeding in adolescents with disabilities — thus providing an option for menstrual management in this population with special needs, in whom data on IUD use are lacking.
Combining the oral GnRH* receptor antagonist relugolix together with oestradiol and the progestin norethindrone helps protect against bone loss induced by oestrogen deprivation associated with the use of GnRH receptor antagonist monotherapy for treating heavy menstrual bleeding, according to the LIBERTY studies released during the ACOG 2020 Meeting.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS JPOG - Malaysia digital copy today!
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.